Evidence map›Paper›PMID 25248763›Full record

ArticleCancer immunology research2014

Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.

Maxine R Miller, Jonathan B Mandell, Kelly M Beatty, Stephen A K Harvey, Michael J Rizzo, Dana M Previte, Stephen H Thorne, Kyle C McKenna

Abstract read
In one paragraph

Article in Cancer immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Splenectomy and risk of hepatocellular carcinoma.World journal of hepatology · 2025
    Review
  2. Review
  3. Article
  4. Beyond the tumour microenvironment.International journal of cancer · 2019
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maxine R MillerDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jonathan B MandellDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Kelly M BeattyDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Stephen A K HarveyDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Michael J RizzoDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania. Graduate Program in Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Dana M PreviteDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania. Graduate Program in Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Stephen H ThorneDepartment of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania. Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Kyle C McKennaDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania. Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. kmckenna@franciscan.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ethan A Rossi · 1989 to 2026
$17.8M
Mechanisms of Immune Evasion by Ocular TumorsR01EY018355 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCKENNA, KYLE C · 2008 to 2012
$1.9M
NCI NIH HHS P30 CA047904NCI NIH HHS P30-CA047904NEI NIH HHS P30 EY008098NEI NIH HHS P30-EY08098NEI NIH HHS R01 EY018355
6 · The paper itself

Abstract

Ocular immune privilege (IP) limits the immune surveillance of intraocular tumors as certain immunogenic tumor cell lines (P815, E.G7-OVA) that are rejected when transplanted in the skin grow progressively when placed in the anterior chamber of the eye. As splenectomy (SPLNX) is known to terminate ocular IP, we characterized the immune mechanisms responsible for rejection of intraocular tumors in SPLNX mice as a first step toward identifying how to restore tumoricidal activity within the eye. CD8(+) T cells, IFNγ, and FasL, but not perforin, or TNFα were required for the elimination of intraocular E.G7-OVA tumors that culminated in destruction of the eye (ocular phthisis). IFNγ and FasL did not target tumor cells directly as the majority of SPLNX IFNγR1(-/-) mice and Fas-defective lpr mice failed to eliminate intraocular E.G7-OVA tumors that expressed Fas and IFNγR1. Bone marrow chimeras revealed that IFNγR1 and Fas expression on immune cells was most critical for rejection, and SPLNX increased the frequency of activated macrophages (Mϕ) within intraocular tumors in an IFNγ- and Fas/FasL-dependent manner, suggesting an immune cell target of IFNγ and Fas. As depletion of Mϕs limited CD8 T cell-mediated rejection of intraocular tumors in SPLNX mice, our data support a model in which IFNγ- and Fas/FasL-dependent activation of intratumoral Mϕs by CD8(+) T cells promotes severe intraocular inflammation that indirectly eliminates intraocular tumors by inducing phthisis, and suggests that immunosuppressive mechanisms that maintain ocular IP interfere with the interaction between CD8(+) T cells and Mϕs to limit the immunosurveillance of intraocular tumors.

Indexed as

AnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalEye NeoplasmsFas Ligand Proteinfas ReceptorFemaleInflammationInterferon-gammaLymphocytes, Tumor-InfiltratingMacrophage ActivationMacrophagesMaleMiceMice, KnockoutFas Ligand Proteinfas ReceptorInterferon-gammaReceptors, Interferon

Identifiers

PMID25248763
PMCPMC4258428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.